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We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by
protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months
as adjuvant treatment in colorectal cancer. A total of 716 patients with curatively resected Dukes’ B or C colorectal cancer were
randomised to 5-FU/FA (5-FU 425mgm
 2 i.v. and FA 20mgm
 2 i.v. bolus days 1–5 every 28 days for 6 months) or to PVI 5-FU
alone (300 mgm
 2 day for 12 weeks). With a median follow-up of 19.8 months, 133 relapses and 77 deaths have been observed.
Overall survival did not differ significantly (log rank P¼0.764) between patients receiving 5-FU/FA and PVI 5-FU (3-year survival 83.2
vs 87.9%, respectively). Patients in the 5-FU/FA group had significantly worse relapse-free survival (RFS, log rank P¼0.023) compared
to those receiving PVI 5-FU (3-year RFS, 68.6 vs 80%, respectively). Grades 3–4 neutropenia, diarrhoea, stomatitis and severe
alopecia were significantly less (Po0.0001) and global quality of life scores significantly better (Po0.001) for patients in the PVI 5-FU
treatment arm. In conclusion, infused 5-FU given over 12 weeks resulted in similar survival to bolus 5-FU and FA over a 6 month
period, but with significantly less toxicity.
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Approximately 1 million new cases of colorectal cancers were
diagnosed worldwide per annum with 500000 patients dying from
the disease in 2000 (Ferlay et al, 2001). Despite potentially curative
surgery, nearly 40% of patients still experience disease relapse
leading to significant morbidity or eventually mortality.
A number of randomised clinical trials performed over the last
two decades have established the role of adjuvant therapy in
Dukes’C (stage III) node-positive colon cancer. The mature results
from the US Intergroup 0035 study showed a 40% reduction in
recurrence and 33% reduction in mortality (Moertel et al, 1990,
1995). This led a National Institute of Health Consensus
Conference to recommend 5-fluorouracil (5-FU)/levamisole to be
given for 12 months as adjuvant therapy in patients with stage III
colon cancer (NIH Consensus Conference, 1990). The efficacy of 5-
FU and folinic acid (FA) as adjuvant therapy was confirmed in the
Intergroup-0085, NSABP C-03 and IMPACT-1 studies (Wolmark
et al, 1993; International Multicentre Pooled Analysis of Colon
Cancer Trials (IMPACT) investigators, 1995; O’Connell et al, 1997).
Furthermore, there appeared to be no detrimental effect on
survival in reducing treatment duration from 12 to 6 months
(O’Connell et al, 1998). The role of adjuvant therapy in Dukes’ B
(stage II) colon cancer remains controversial with conflicting
evidence and no international consensus (International
Multicentre Pooled Analysis of B2 Colon Cancer Trials
(IMPACT B2) Investigators, 1999; Mamounas et al, 1999; Taal
et al, 2001).
Adjuvant chemotherapy has also been used in Dukes’ B and C
rectal cancer and has been shown to improve survival compared to
surgery alone (Fisher et al, 1988), and the efficacy of adjuvant 5-
FU/FA in rectal cancer has also been demonstrated (Wolmark et al,
2000; Tepper et al, 2002). Although a significant reduction in local
recurrence is observed, postoperative radiotherapy has not
impacted on survival – an observation confirmed in a recent
meta-analysis (Colorectal Cancer Collarborative Group, 2001).
Radiotherapy (RT) is often used in conjunction with chemother-
apy in rectal cancer. Whereas postoperative chemoradiation has
been shown to produce superior survival compared to surgery
(Gastrointestinal Tumor Study Group, 1985; Douglass Jr et al,
1986) or radiotherapy alone (Krook et al, 1991), no survival
advantage has been demonstrated compared to chemotherapy
alone (Gastrointestinal Tumor Study Group, 1985; Wolmark et al,
2000).
Two bolus 5-FU/FA dose schedules – Mayo clinic regimen (5-FU
425mgm
 2 and FA 20mgm
 2 days 1–5 every 4 weeks for six
cycles) or Roswell Park Regimen (5-FU 500mgm
 2 and FA
500mgm
 2 weekly 6 every 8 weeks for three to four cycles) –
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lhave been widely adopted as the reference adjuvant therapy for
colon cancer. Protracted intravenous infusion of 5-FU (PVI 5-FU)
has been shown to result in higher response rate and lower
haematological toxicity compared to bolus injection in patients
with advanced colorectal cancer (Lokich et al, 1989). In a meta-
analysis of six randomised studies, prolonged infusion of 5-FU
resulted in less haematological toxicity and a small but statistically
significant survival advantage over bolus regimen (Meta-analysis
Group In Cancer, 1998), thus providing the rationale to investigate
infused 5-FU as adjuvant therapy. Furthermore, the use of PVI 5-
FU during radiation has been shown to improve survival
compared to bolus 5-FU in rectal cancer (O’Connell et al, 1994).
In this prospective randomised study, we compared the efficacy of
PVI 5-FU against bolus 5-FU/FA as adjuvant therapy in patients
with potentially curative resected colorectal cancer. The duration
of chemotherapy in the PVI-5-FU arm was shortened to 12 weeks
since this still has twice the total intended 5-FU dose
delivery compared to bolus schedule (25.2 vs 12.75 gm
 2,
respectively). Moreover, in published literature, the greatest
improvement in survival was noted in studies in which the largest
dose of 5-FU was planned, particularly over the first 3 months
(Zalcberg et al, 1996).
PATIENTS AND METHODS
Patient eligibility
Patients were entered into the study within 12 weeks of curative
resection of Dukes’ B or C adenocarcinomas of the colon or
rectum, providing there was no evidence of metastatic disease as
assessed by postoperative radiological and carcinoembryonic
antigen (CEA) evaluation. Surgical specimens or representative
slides were reviewed in the histopathology department at the
participating centres to confirm tumour stage and resection
margin status. Circumferential resection margins were required
to be clear by at least 1mm in patients with rectal cancer. Tumours
were classified as rectal if they arose below the peritoneal reflection
or were within 12cm of the anal verge. Patients with histopatho-
logically confirmed tumour extension into adjacent organs were
eligible if all tumour had been removed and the resection margins
were confirmed as being clear. Patients were required to have
adequate bone marrow, renal and liver function and no concurrent
severe or life-threatening illness. Preoperative RT was allowed in
patients with rectal cancer.
Participating patients gave written informed consent before
they entered the study. The protocol was approved by the Scientific
and Research Ethics Committee of the institutions taking
part as well as the North Thames Multi-centre Research Ethics
Committee.
Randomisation procedure
Details of all eligible patients were forwarded to the data manager’s
office based at the Royal Marsden Hospital, Surrey, UK to verify
eligibility criteria. Patients were then randomly assigned by an
independent randomisation office to either bolus 5-FU/FA or PVI
5-FU in a 1:1 basis using random permuted blocks. Randomisa-
tion was stratified by treatment centre and in cases of rectal cancer,
whether preoperative RT was given.
Chemotherapy
Patients were randomly allocated to one of the following
treatments:
1. 5-fluorouracil alone by protracted venous infusion (PVI 5-FU).
This was administered via a skin-tunnelled central venous catheter
placed in the subclavian vein (Hickman line). Warfarin
(1mgday
 1) was administered to prevent catheter thrombosis.
5-fluorouracil was given as a continuous intravenous infusion
at a dose of 300mgm
 2day
 1 using a portable pump for
12 weeks.
2. Intermittent bolus 5-FU and folinic acid (5-FU/FA). Folinic
acid at a dose of 20mgm
 2 per day was administered as a bolus
intravenous injection followed by a bolus injection of 5-FU at a
dose of 425mgm
 2 on five consecutive days, repeated every 28
days for a total of 6 cycles. In 1998, the protocol was amended so
that the starting dose of bolus 5-FU was reduced to 370mgm
 2 for
patients aged over 70 years.
Radiotherapy
In this study, patients with rectal cancer were not routinely treated
with combined modality therapy. The addition of adjuvant
radiotherapy was specifically reserved for those patients at high
risk of locoregional failure (T4 tumours). Post-operative radio-
therapy was delivered as 45Gy in 25 fractions to the pelvis with a
5.4Gy boost in three fractions to the tumour bed. Irradiation was
initiated to coincide with the 4th cycle of bolus therapy or after
completion of 12 weeks of PVI 5-FU, which continued at a reduced
dose of 200mgm
 2 until completion of radiotherapy. For patients
in the 5-FU/FA arm, the dose modification was to reduce
5-FU by 75mgm
 2day
 1 and to truncate the duration to 4 days
commencing at the 4th cycle. Cycle 5 was delivered during
radiotherapy and cycle 6 was delivered following completion of
radiotherapy.
Toxicity assessment and dose modifications
Adverse effects were graded according to National Cancer Institute
Common Toxicity Criteria. Nonhaematological grade 1 toxicities
were treated as follows: diarrhoea-codeine phosphate 30–60mg
p.o. qds, stomatitis-sucralfate 1g qds, and plantar-palmar erythe-
ma-pyridoxine 50mg p.o. tds. If symptoms did not improve with
these measures or toxicities were greater than grade 2 at onset, the
5-FU infusion was suspended until toxicity resolved (usually 7–10
days). In the PVI 5-FU arm, dose reductions of 50, 100 and
150mgm
 2 were made for grades 2, 3 and 4 toxicities, respectively.
In the 5-FU/FA arm, 5-FU dose reductions of 25, 50 and 50% of full
dose were made for grades 2, 3 and 4 nonhaematological toxicities,
respectively. In addition, if white blood count was o3.0 10
9l
 1,
absolute neutrophil count was o1.5 10
9l
 1 and platelet count
was o100 10
9l
 1 on the day of treatment, both 5-FU and FA
would be withheld for 1 week. If dose delay for 2 weeks was
required, all subsequent 5-FU treatment would be given at 75% of
full dose. If delay of 42 weeks was required, all subsequent 5-FU
treatment would be given at 50% of full dose. No dose reductions
were made to FA for toxicity.
Quality of life (QOL) assessment
The multidimensional health-functioning questionnaire from the
European Organisation for Research and Treatment of Cancer
(EORTC QLQ-C30) was used to assess QOL of patients undergoing
chemotherapy. Scoring was made according to the guidelines
provided by the EORTC QOL group, using standardised proce-
dures. Scores were measured weekly in the first month of
treatment and then at monthly intervals.
Follow-up assessment
Following completion of chemotherapy, patients were seen every 3
months until 1 year from the start of chemotherapy and then six-
monthly. Carcinoembryonic antigen was estimated at each clinical
visit. Re-evaluation CT scans were performed 12 and 24 months
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months after the start of chemotherapy.
Statistical methods
The accrual goal was set at 716 patients, which was calculated to
detect a minimal improvement in patient survival from 60 to 70%
after 5 years of follow up (358 patients per arm to provide at least
80% power in a two-sided test a¼5%). The primary end point in
this study was death from any cause. Secondary end points were
relapse-free survival (RFS), toxicity and QOL. For RFS, an event
was defined as either recurrence of cancer or a second primary
tumour. Eligible patients were analysed by intention to treat.
Survival and duration of relapse-free interval was estimated with
the Kaplan–Meier product limit method (Kaplan and Meier, 1958),
and treatment arms were compared using the log-rank test (Peto
and Peto, 1972). Treatment toxicities in the two arms were
compared using the w
2 test. Changes in QOL scores from baseline
were compared for the two arms using a nonparametric Mann–
Whitney test.
Univariate analysis was stratified by treatment centre and
performed using the log-rank test to identify characteristics
predictive for survival. The prognostic factors analysed for effect
were performance status, age, gender, site of primary tumour,
treatment arm and tumour differentiation. Multivariate survival
analysis was performed using Cox’s proportional hazards model
(Cox and Oakes, 1984) and corrected for all the above prognostic
factors.
RESULTS
In total, 716 patients with colorectal cancer from seven oncology
centres in the UK were randomised. A total of 24 patients (3.4%)
were ineligible mostly (20 out of 24) as a result of either
unexpected metastatic disease or positive margins on review; 10
had been allocated to 5-FU/FA and 14 to PVI 5-FU (Figure 1). The
remaining 692 patients were analysed by intention to treat.
Patient characteristics
The pretreatment characteristics of patients are listed in Table 1.
Age, gender, performance status, Dukes’ stage, differentiation and
Table 1 Characteristics of eligible patients (%)
5-FU/FA PVI 5-FU Total
n 350 342 692
Age (years)
Median 63 63 63
Range (28–95) (27–82) (27–95)
Gender
Male 181 (52) 180 (53) 361 (52)
Female 169 (48) 162 (47) 331 (48)
Site of primary tumour
Colon 234 (67) 240 (70) 474 (68)
Rectum 116 (33) 102 (30) 218 (32)
Differentiation
Well 11 (3) 14 (4) 25 (4)
Moderately 293 (84) 272 (80) 565 (82)
Mod-Poorly 0 (0) 1 (0.3) 1 (0.1)
Poorly 35 (10) 37 (11) 72 (10)
Unknown 11 (3) 18 (5) 29 (4)
Dukes’ stage (colon)
B 105 (45) 103 (43) 208 (44)
C 127 (54) 131 (55) 258 (54)
Unavailable 2 (1) 6 (2) 8 (1)
Dukes’ stage (rectum)
B 41 (35) 42 (41) 83 (38)
C 75 (65) 60 (59) 135 (62)
Performance status
0 159 (45) 174 (51) 333 (48)
1 162 (46) 140 (41) 302 (44)
2 20 (6) 22 (6) 42 (6)
Unknown 9 (3) 6 (2) 15 (2)
Radiotherapy received for rectal
cancer patients (n¼218)
Preoperative 10 (5) 4 (2) 14 (7)
Postoperative
a 10 (5) 15 (7) 25 (12)
Figures in parentheses denote percentages of patients apart from age range.
aAs part of the study protocol.
    716 patients randomised 
360 assigned 5-FU/FA 356 assigned PVI 5-FU 
        350 analysed          342 analysed 
14 ineligible  10 ineligible 
Figure 1 Trial profile.
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lsite of primary tumour were well matched between the treatment
arms. Among 218 patients with rectal cancer, the operations
performed were abdominal perineal resection (26%), anterior
resection (69%) and others (5%). The proportion of patients
undergoing each type of procedure was evenly distributed between
the treatment arms. There was no difference in median time of
starting chemotherapy from date of surgery – 7.7 weeks for
patients in the 5-FU/FA arm vs 8 weeks for patients in the PVI 5-
FU arm (P¼0.143).
Survival
This analysis was carried out at the completion of accrual, when
the median duration of follow-up was 19.8 months (range 0–70)
and 77 patients have died (11%). Figure 2 shows the overall
survival for the two treatment arms. There was no significant
differences between the two arms (log rank P¼0.764). The 3-year
survival was 83.2% (95% confidence interval (CI): 77–87.9%) for
the 5-FU/FA group and 87.9% (95% CI: 83–92%) for the PVI 5-FU
group. On further examination, the probability of PVI 5-FU being
inferior to 5-FU/FA was only 0.0560, based on a 75% difference in
3-year survival being ruled out. Similarly, there were no significant
differences between the two treatment groups when patients were
separated according to Dukes’ stage (B vs C) or tumour sites (colon
vs rectum). On multivariate analysis, Dukes’ staging and age were
significant prognostic factors whereas treatment arm was not
prognostic (Table 2). However for patients with rectal cancer, there
was a trend towards worse survival for bolus 5-FU/FA arm
(P¼0.08).
Relapse
A total of 88 (19%) patients with colon cancer and 45 (21%)
patients with rectal cancer had relapsed. Figure 3 shows the RFS
for the two treatment arms. Patients treated with 5-FU/FA had
significantly higher rate of relapse compared to those with
PVI 5-FU (log rank P¼0.023). The 3-year RFS was 68.3% (95%
CI: 60.7–73.6%) for 5-FU/FA and 80% (95% CI: 72.9 – 83.9%) for
PVI 5-FU.
Less relapses occurred in patients with Dukes’ B cancer treated
with PVI 5-FU (P¼0.028), whereas no difference in relapse
between the treatment arms was seen in patients with Dukes’ C
cancer (P¼0.33). Relapses were significantly less in patients with
rectal cancer treated with PVI 5-FU (P¼0.007).
On multivariate analysis, treatment with 5-FU/FA was associated
with worse RFS (P¼0.043), but this effect was found to be limited
to the subgroup of patients with rectal cancer. For these patients,
the 5-FU/FA arm was 2.38 (95%CI: 1.27–4.45) times more at risk
of relapse than those in the PVI 5-FU arm. Dukes’ staging was also
a significant prognostic factor for RFS (Table 3).
Toxicity
There were no chemotherapy-related deaths in this study. Table 4
shows the incidences of grades 3–4 toxicities. Highly significant
reduced incidences of diarrhoea, stomatitis and neutropenia
occurred in patients treated with PVI 5-FU compared with 5-FU/
FA. Grade 2 alopecia occurred in 25% of female patients treated
with 5-FU/FA compared with 0.6% of those treated with PVI 5-FU.
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Figure 2 Overall survival.
Table 2 Multivariate analysis for overall survival
Variables P
Hazard
ratio
a 95% CI
All patients Treatment arm 0.782 – –
Age 0.032 1.026 1.00 – 1.05
Dukes’ stage 0.004 2.052 1.25 – 3.36
Colon Treatment arm 0.397 – –
Dukes’ stage 0.002 2.581 1.41 – 4.74
Rectal Treatment arm 0.08 2.254 0.91 – 5.60
Age 0.023 1.060 1.01 – 1.12
aHazard ratio (HR) for Dukes’ stage is expressed as Dukes’ C over B; hence,for all
patients, Dukes’ C tumours has 2.052 times higher risk of death compared to Dukes’
B tumours. HR for treatment arm is expressed as 5-FU/FA over PVI 5-FU; hence in
rectal cancer, 5-FU/FA arm has 2.254 times higher risk of death compared to PVI 5-
FU arm.
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Figure 3 Relapse-free survival.
Table 3 Multivariate analysis for RFS
Variables P
Hazard
ratio
a 95% CI
All patients Treatment arm 0.043 1.442 1.01 – 2.06
Dukes’ stage o0.001 2.362 1.62 – 3.45
Colon Treatment arm 0.637 – –
Dukes’ stage o0.001 2.695 1.68 – 4.32
Rectal Treatment arm 0.007 2.380 1.27 – 4.45
Dukes’ stage 0.047 1.922 1.01 – 3.66
aHazard ratio (HR) for Dukes’ stage is expressed as Dukes’ C over B; hence, for all
patients, Dukes’ C tumours has 2.362 times higher risk of relapse compared to
Dukes’ B tumours. HR for treatment arm is expressed as 5-FU/FA over PVI 5-FU;
hence, in rectal cancer, 5-FU/FA arm has 2.38 times higher risk of relapse compared
to PVI 5-FU arm.
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lThere was also a significant difference in the incidence of grades
1–4 nausea and vomiting (66 vs 25% for 5-FU/FA and PVI 5-FU
groups, respectively, Po0.0001). Although the incidences of grades
3–4 palmar-plantar syndrome were low in both treatment arms,
72.5% of patients receiving PVI 5-FU developed Xgrade 1 palmar-
plantar syndrome compared with 47.5% of patients receiving 5-
FU/FA (Po0.001). No difference was seen between the two
treatment arms for incidence of infection or febrile episodes. For
patients in the 5-FU/FA arm of the study, the number of
emergency admissions was significantly greater (0.95 vs 1.73 in-
patient bed-days, P¼0.008) for the cohort of patients treated at
Royal Marsden Hospital.
Data on adverse effects associated with Hickman lines were
available for 342 of lines inserted. Serious complications were
infrequent including pneumothorax (n¼2, 0.6%) septicaemia
(n¼4, 1.2%) and thrombotic complications (n¼25, 7%). The
most frequently reported problem was superficial cutaneous
infection at the line entry site, which affected 24% of Hickman
lines. Other problems consisted of pain from the line entry site,
shoulder, arm, back or chest, which was reported in 42 cases
(12%). Only 9% of patients underwent removal and resiting of
their Hickman lines.
Chemotherapy dose intensity
The average planned dose of 5-FU per patient was 12750 and
25200mgm 2 for the 5-FU/FA and PVI 5-FU patients, respec-
tively. Largely, as a consequence of the dose reductions and delays
arising from toxicity, patients in the bolus treatment group
received on average 74% of their intended dose, while those in the
PVI group received 90% of the intended dose (Po0.001). The
proportions of patients who did not have any dose reductions,
delays or interruptions during the entire treatment programme in
the 5-FU/FA and PVI 5-FU groups were 13.3 and 45.7%,
respectively.
Quality of life
At baseline, there was no difference in the global QOL scores
between patients randomised to either 5-FU/FA or PVI 5-FU (72.0
vs 73.2, respectively, P¼0.473, Figure 4). The lowest scores for
both groups were noted at the 2-week time point, but were
significantly worse for patients receiving 5-FU/FA compared to
those receiving PVI 5-FU (59.3 vs 68.6; Po0.001). At the 4-week
time point, QOL scores for the patients in the both treatment
groups equalised, coinciding with the resolution of toxicity. At 24
weeks, global scores were 74.2 and 78.8 for 5-FU/FA and PVI 5-FU,
respectively (Po0.001), but in the follow-up period beyond 24
weeks there was no significant difference between the arms. Both
arms displayed significantly increased global QOL in the follow-up
period compared to the baseline.
DISCUSSION
The data from this prospective randomised trial demonstrated the
efficacy of 12 weeks’ PVI 5-FU in the adjuvant setting and provide
a direct comparison of the toxicity of this treatment against a
standard bolus regimen. For survival there is only a 5.6% chance
that PVI 5-FU is inferior to 5-FU/FA. The advantage of PVI 5-FU
over 5-FU/FA is reflected by a number of parameters including
toxicity and QOL. Furthermore, halving treatment duration to 12
weeks by the use of PVI 5-FU appears not to be detrimental to
survival in this setting.
Previous studies designed to address the question of duration of
adjuvant chemotherapy have demonstrated that 6 months of
therapy provides a survival effect similar to that of 12 months
(O’Connell et al, 1998). Survival data from the present report are
derived from an analysis which was carried out when the accrual
Table 4 Incidences of grades 3 and 4 toxicities
% Worst-grade toxicity 5-FU/FA PVI 5-FU P
Stomatitis 19.6 3.6 o0.0001
Nausea/vomiting 2.6 1.8 0.46
Diarrhoea 16.0 5.4 o0.0001
Alopecia
a 14.3 0.3 o0.0001
Palmar-plantar syndrome 3.5 6.3 0.09
Infection 5.5 3.3 0.153
Leucopenia 10.3 0.6 o0.0001
Neutropenia 55.6 0.9 o0.0001
Thrombocytopenia 1.5 0.6 0.12
Anaemia 2.1 1.2 0.37
aGrade 2.
P=0.048
P=0.913
P<0.001
P<0.001
P<0.001
P<0.001
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Figure 4 Global QOL scores (solid line PVI 5-FU, dotted line 5-FU/FA) EORTC Core 30 Global QOL scores with 95% confidence intervals. Fup yr:
follow-up year.
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lgoal was reached and consequently, the duration of follow-up is
relatively short with a median of only 19.8 months. However, PVI
5-FU given over 12 weeks has an effect on survival, which seems
very unlikely to be inferior to that achieved by the administration
of 6 months of chemotherapy with bolus 5-FU/FA. The 3-year
survival of 88% in the PVI 5-FU arm corresponds to data from two
other recently reported large-scale adjuvant studies in which a
comparable patient population has been treated, that is, both
Dukes’ B and C and both colon and rectal cancers (QUASAR
Collaborative Group, 2000; Taal et al, 2001).
When patients were analysed according to site of primary
tumour, the subgroup with rectal tumours who underwent
treatment with PVI 5-FU had a significantly prolonged time to
relapse and a significant overall reduction in tumour recurrence
compared to those receiving the standard regimen (P¼0.043). In
addition, there was a trend towards improved survival (P¼0.08).
In this group, the number of patients receiving either preoperative
or postoperative radiotherapy was balanced between the two
treatment arms. These results are consistent with those seen with
the US Intergroup study in which patients treated with PVI 5-FU
during radiation has improved RFS and overall survival compared
to bolus 5-FU (O’Connell et al, 1994). Although FA was not used in
the bolus 5-FU arm in this Intergroup study, there is no evidence
to suggest combination of bolus 5-FU/FA is superior to 5-FU alone
during radiation (Tepper et al, 2002). However, this finding in our
study is based on a relatively small number of events and was the
result of an unplanned subgroup analysis. To confirm this initial
observation, our study has been extended for patients with rectal
cancer.
Two studies comparing prolonged infusion of 5-FU with bolus
regimen of 5-FU have been reported. A French study coordinated
by GERCOR (Groupe d’Etude et de Recherche Clinique en
Oncologie Radiotherapies) compared 2-weekly infused 5-FU/FA
with bolus 5-FU/FA and a second randomisation to either 24 or 36
weeks of treatment. With 905 patients recruited, treatment was less
toxic in the infused 5-FU/FA arm with significantly lower
incidence of grades 3 and 4 neutropenia, diarrhoea and mucositis
(Po0.001) (Andre et al, 2001). This is consistent with our study in
which PVI 5-FU resulted in much better toxicity profile. No
differences in disease-free survival were seen between the
treatment arms or between different durations of treatment in
the GERCOR study (Andre et al, 2002). In the Intergroup-0153
study, continuous infusion of 5-FU with levamisole was compared
to bolus 5-FU/FA and levamisole. Interim analysis showed a 3-year
survival of 76% for the infused arm, but the study was prematurely
closed because the infused arm was unlikely to produce a survival
advantage even if the accrual goal was completed (Poplin et al,
2000).
However, one of the critical issues in trials of adjuvant therapy
for cancer patients is whether the size of the survival benefit is
worth the decline in QOL caused by adverse effects of treatment. In
the Intergroup-0035 study, which led to the recommendation of 1
year of 5-FU and levamisole as adjuvant therapy, 30% of patients
discontinued treatment prematurely because of toxicity with a
median of 5 months’ treatment (Moertel et al, 1990). Aside from
the potential impact of treatment-induced toxicity on patients’
QOL, there is a detrimental impact on the actual dose of 5-FU
which can be delivered. The findings of the present study showed
that the higher rate of grades 3–4 toxicities experienced by
patients on 5-FU/FA arm resulted in only 74% of the intended dose
of 5-FU being delivered, while the favourable toxicity profile of PVI
5-FU enables patients to receive 90% of the prescribed dose.
In a previous study of patients undergoing treatment for
metastatic disease, 30% of 560 catheters required premature
removal because of complications (Ray et al, 1996). However, our
results show that the most frequent complications were minor
superficial infection at the line entry site, while the rate of
thrombotic complications was relatively low at 7%. Only 9% of
patients required a change of line. Fewer line changes in this study
are likely to have arisen as a result of the lower incidence of
thrombotic complications expected for patients undergoing
therapy in the adjuvant setting compared to those with advanced
disease. The constraints of having an indwelling line and portable
electronic pumps were not associated with a negative impact on
QOL, which was measured in this study by sequential QOL self-
assessment. The QOL scales used detected a significant difference
between the two treatment groups at the 2-week time point
following initiation of treatment and favoured the PVI treatment
arm. After this time point, there was no difference observed for the
two groups while on treatment. However, on cessation of treatment
(in the PVI 5-FU arm) at 12 weeks, a significant difference in the
global QOL scores again emerged, these QOL scores improved to
above baseline levels for both treatment groups after the
completion of therapy, but was earlier for patients receiving PVI
5-FU.
Oral fluoropyrimidines provide prolonged 5-FU exposure at
lower peak concentrations than those observed with bolus 5-FU
schedule, thereby simulating continuous infusion of 5-FU. They
have been shown to have similar survival to bolus 5-FU/FA in
advanced disease setting and provide the same favourable toxicity
profile seen with PVI 5-FU (Hoff et al, 2001; Van Cutsem et al,
2001; Carmichael et al, 2002; Douillard et al, 2002). Two trials have
finished recruitment evaluating capecitabine and UFT as adjuvant
therapy in colon cancer, and if their efficacy is proven in the
adjuvant setting, one may be able to avoid the morbidity and
inconvenience associated with central venous catheters and
infusion pumps required for continuous intravenous infusion of
5-FU.
In conclusion, this study has demonstrated that the adminis-
tration of infused 5-FU as adjuvant therapy is associated with less
acute toxicity and less impairment of QOL than a standard bolus
schedule. Furthermore, this has been achieved without any
obvious adverse effect on outcome, and indeed there appears to
be improved outcome, in the group of patients with rectal cancer.
Reducing treatment duration to 12 weeks was not associated with
any detrimental effects on the efficacy of infused 5-FU.
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